Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!
The purpose of this study is to understand how children’s brains process sounds and language. Children with Autism Spectrum Disorder (ASD), Intellectual and Developmental Delay (IDD), or Developmental Language Disorder (DLD) often have trouble understanding sounds that are too close together compared to Typically Developing Controls (children without ASD, IDD, or DLD). Fast changes in speech can be hard for children. This may be awkward during conversations and difficult in social situations. This research will see if trouble with processing sounds contributes to language difficulties in children with ASD, IDD, and/or DLD.
This study involves taking a study drug called venetoclax with or without standard of care chemotherapy. The overall goal of this study is to see if adding venetoclax to standard chemotherapy leads to improved survival for children and young adults with relapsed acute myeloid leukemia (AML). The study may last up to 9 years and will enroll male and female patients from the ages of 29 days to 21 years of age.
The purpose of this study is to find out if the study drug, MAS825, is effective in preventing flares and safe for children with NLRC4-Gain of Function (GOF). Researchers will also be testing how the body processes a drug by measuring how quickly the drug is absorbed by the body, how quickly it is broken down by the body, and how long it remains in the body (pharmacokinetics). Subjects will be asked to come into the Rheumatology clinic for blood and stool testing, physical exam, an electrocardiogram (ECG), questionnaire completion, and administration of study drug. Participation will last for up to 4 years.
CHOP in collaboration with AbbVie, is conducting a study for pediatric patients from 1 year of age to 25 years of age with relapsed or refractory aggressive mature B-cell neoplasms (including diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukemia). In this clinical trial, participants will receive the study drug epcoritamab, an immune therapy. Epcoritamab is in clinical development and is being studied for an unapproved use in pediatric patients with B-cell neoplasms. It is not approved for use by the FDA or other global regulatory health authorities. Safety and efficacy are under evaluation. For more information about this study, including specific eligibility criteria, please visit clincialtrials.gov and search for “NCT05206357”. To hear more about this and other available trials or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@chop.edu.
The goal of this study is to find out if we can develop a digital health approach that can increase sleep duration and improve growth outcomes in children.
Are you interested learning about opportunities to participate in research? Sign up to receive information about new research studies at CHOP. It’s a great way to support the work of the Research Institute.